" class="no-js "lang="en-US"> OmniSeq - Medtech Alert
Wednesday, September 03, 2025
OmniSeq | Pharmtech Focus

OmniSeq

About OmniSeq

OmniSeq

OmniSeq, an innovation of Roswell Park Cancer Institute, is a molecular diagnostic laboratory based in Buffalo, New York. OmniSeq endeavors to find the right drug or the right trial for every patient by improving access to better cancer treatment options through molecular profiling.

In addition to other NY State CLEP approved assays, OmniSeq offers OmniSeq Comprehensive and Immune Report Card. These two assays are available clinically in the United States and interrogate all known genomic and immune markers tied to approved therapeutics and clinical trials. OmniSeq is also making significant investments to create better diagnostics for immuno-oncology therapy selection. OmniSeq is proud to partner with pharmaceutical companies to provide research support for immuno-oncology development projects.

For more information, call 1-800-781-1259 or visit www.omniseq.com.

Related Story

GenomOncology Pathology Workbench to Support OmniSeq INSIGHT℠, a Genomic and Immune Profiling Test That Identifies Potential Treatment and Clinical Trial Options for Solid Tumors

January 13 2022

GenomOncology announced today that GenomOncology (GO) Pathology Workbench has been selected by Labcorp’s OmniSeq to […]